SCHEMBL24307804

SCHEMBL24307804

O=C1CCCN1c1cnc(N2CCC2)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.44
CYP11B2 P19099 1/20 0.42
ALOX5AP P20292 2/20 0.40
LMNA P02545 1/20 0.40
AKR1C3 P42330 2/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
FEN1 P39748 1/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRL1 P41146 1/20 0.37
EGLN2 Q96KS0 1/20 0.36
PDK2 Q15119 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24307836 0.85 CYP11B2 (0.41) HTR6CYP11B2ALOX5APAKR1C3MEN1
SCHEMBL13003536 0.79 LMNA (0.44) HTR6CYP11B2LMNAAKR1C3TSHR
SCHEMBL12414652 0.76 HTR6 (0.40) HTR6CYP11B2ALOX5APLMNAAKR1C3
SCHEMBL21299098 0.75 AKR1C3 (0.44) HTR6LMNAAKR1C3MEN1TSHR
SCHEMBL14236720 0.73 LMNA (0.49) LMNAAKR1C3MEN1TSHRKMT2A
SCHEMBL21299020 0.72 HRH3 (0.55) HTR6LMNAAKR1C3MEN1TSHR
SCHEMBL31745141 0.71 CYP11B2 (0.47) HTR6CYP11B2LMNAAKR1C3ALDH1A1
SCHEMBL29640749 0.71 ALDH1A1 (0.50) HTR6LMNAAKR1C3MEN1TSHR
SCHEMBL30066526 0.70 SYK (0.35) ALOX5APFEN1
SCHEMBL16542450 0.70 ALDH1A1 (0.53) LMNAAKR1C3MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3585775-B1 AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS SANOFI SA (FR) 2022-04-06 EP disclosed